DES is an abbreviation for generic diethylstilbestrol (also called stilboestrol), a synthetic hormone designed to prevent miscarriage. A variety of manufacturers sold this drug from the 1940s to the 1970s, and some six million women took the medication over nearly four decades.
After studies corroborated that DES caused serious side effects, including vaginal cancer, in women who were exposed to the drug while in the womb, DES was pulled off the market. Breast cancer also seems to be linked to pre-birth exposure to the medicine, and as a result, lawsuits by women suffering from this form of cancer have ensued against DES manufacturers Eli Lilly and Bristol Myers Squibb.
It may be difficult to prove a link to a specific DES manufacturer and this may not required in all jurisdictions. If you or someone you know may have been exposed to DES in the womb and are now suffering from cancer, we need to hear from you. Call us to see if your individual DES case may be eligible for potential financial compensation.